With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Aberrant DNA methylation in Ewing sarcoma.||Fred Hutchinson Cancer Research Center / Scott Borinstein||Young Investigator Grants||2009||Washington|
|Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children||Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD/PhD||Reach Grants||2018||Washington|
|HA-1 TCR T-cell Immunotherapy for Acute Leukemia||Fred Hutchinson Cancer Research Center / Marie Bleakley, M.D., Ph.D.||Bio-Therapeutic Impact Award||2014||Washington|
|Exploiting the Potential of Bromodomain Inhibitors in Ewing Sarcoma||Seattle Children's Hospital / Shireen Ganapathi, MD||Young Investigator Grants||2021||Washington|
|Prognostic and Therapeutic Significance of Stem Cell Heterogeneity in AML||Fred Hutchinson Cancer Research Center / Roland Walter, MD, PhD||'A' Award Grants||2012||Washington|
|Critical Contributions of CRM1 to Leukemogenesis||University of Vermont / Jessica Linda Heath, MD||Young Investigator Grants||2015||Vermont|
|TrkB Signaling in the Genesis of Murine Neuroblastoma||University of Vermont / Rae Nishi, PhD||Innovation Grants||2007||Vermont|
|Small Molecule Inhibitors of ERG for Pediatric Leukemia and Sarcoma||University of Virginia, School of Medicine / John Bushweller, PhD||Innovation Grants||2015||Virginia|
|LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma||University of Virginia, School of Medicine / Michael Engel, MD/PhD||Reach Grants||2016||Virginia|
|Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma||Virginia Commonwealth University / Anthony Faber, MD & Yael Mosse, MD (CHOP)||Innovation Grants||2015||Virginia|